CH BIOTECH SER (08037) has completed the sale of the entire issued share capital of Standard Pathology Laboratory and ZHOKI Healthcare.

CH BIOTECH SER (08037) announced the sale of all issued share capital of Standard Pathology Laboratory Limited and Zhuoji Health Limited. All preconditions contained in the sale agreement have been met, and the sale was completed on August 13, 2026, in accordance with the terms and conditions of the sale agreement. Immediately after completion and on the date of this announcement, Standard Pathology Laboratory and Zhuoji Health will no longer be subsidiaries of the Group, and the financial performance of Standard Pathology Laboratory and Zhuoji Health will no longer be consolidated into the Group's financial performance. The sale of the laboratory testing business is a key step in the Group's strategic business transformation. By divesting the continuously loss-making Hong Kong laboratory testing business, the Group can reallocate its human, financial, and operational resources to focus on developing the complete industrial chain of boron neutron capture therapy (BNCT), including medical services, drugs, and equipment, with the aim of building a boron neutron technology industry platform that is internationally synchronized and domestically leading.